Abstract: The present invention relates to a motor driving control system and a control method thereof. The purpose of the present invention is to provide a motor driving control system and a control method thereof, which may change electric current limiting logic, which is applied to a BLDC motor for a cooling fan, in response to an operating speed of the motor to stably protect the motor from an overload in a low-speed driving state as well as an overload in a high-speed driving state.

Abstract: Disclosed is a method of producing lithium sulfide (Li2S) without using hydrogen sulfide (H2S) gas. Particularly, the method of producing lithium sulfide (Li2S) includes preparing a starting material including a metal oxide by subjecting a mixed powder including an inorganic compound containing lithium and oxygen, a metal reducing agent, and sulfur (S) to synthesis reaction using mechanical force, preparing a mixed solution by mixing the starting material and a solvent, and obtaining a lithium sulfide (Li2S) powder by removing the metal oxide from the mixed solution and then performing drying.

Abstract: A substrate transfer system capable of performing efficient distribution exchange between fabricating facilities is provided. The substrate transfer system includes a lower rail, an upper rail which is located above the lower rail from a ground plane, and extends to be parallel to the lower rail, a conveyor which extends to intersect the lower rail and the upper rail, below the lower rail, a first lower transport unit which transports a first carrier along the lower rail and unloads the first carrier onto the conveyor, and a first upper transport unit which transports a second carrier along the upper rail and unloads the second carrier onto the conveyor, wherein the conveyor includes a linear module which moves the first carrier and the second carrier in a linear direction, and a turning module which turns the first carrier and the second carrier.

Abstract: A method for sharing data in a transmitting-side electronic device communicating with a receiving-side electronic device is provided. The method includes connecting a voice call with the receiving-side electronic device; obtaining a sharing object to be shared with the receiving-side electronic device; and transmitting data corresponding to the sharing object to the receiving-side electronic device through a data session formed based on information related to the voice call.

Abstract: The present invention relates to a high-temperature superconducting rotating machine system equipped with a fixed type cryostat and a vaporized cryogen re-use cooling structure.

Abstract: An inverter module according to an embodiment of the present invention comprises: a high voltage circuit unit which generates an inverter control voltage and a motor driving voltage by using a first DC voltage; a high voltage circuit pattern which electrically connects the high voltage circuit unit; a low voltage circuit unit which communicates with an external device by using a second DC voltage having a smaller magnitude than the first DC voltage; and a low voltage circuit pattern which electrically connects the low voltage circuit unit. The high voltage circuit pattern and the low voltage circuit pattern are spaced apart from each other.

Abstract: Provided is a testing apparatus for an active current control-type non-contact superconductive exciter having a hybrid magnet installed therein, and a high-temperature superconductive rotating machine using same. Provided is principally characterized by having a hybrid magnet, in a module form, in which a permanent magnet, a DC electromagnet and an AC electromagnet are used together, wherein the hybrid magnet is set in a plurality along the circumferential direction of a ring-shaped iron stator, is formed to correspond to the outer side of a rotor, having a high-temperature superconductive tape (or a second-generation high-temperature superconductive wire), of a non-contact superconductive exciter, and thus enables a selected operation (charging, discharging and the like) before and after rotation of a driving motor.

Abstract: An apparatus of tilting a seat cushion of a vehicle, includes a tilting motor, a pinion gear, a sector gear, and a tilting link which perform the tilting operation of the seat cushion and exert a binding force in a tilted state of the seat cushion and are provided to be connected to both of one side and the other side of a seat cushion frame, and has two sector gears positioned on left and right sides and connected to each other by a connection bar so that, by strengthening a binding force of the front portion of the seat cushion, it is possible to secure the safety of passengers in the event of a collision.

Abstract: A battery module includes: a battery cell assembly having a plurality of battery cells; a top plate configured to cover an upper side of the battery cell assembly; a bottom plate configured to cover a lower side of the battery cell assembly; a sensing assembly disposed to cover a front side and a rear side of the battery cell assembly; a pair of side plates disposed at side surfaces, respectively, of the battery cell assembly; and a pair of compression pads disposed between the pair of side plates and the battery cell assembly, respectively.

Abstract: A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.

Abstract: A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.

Abstract: The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.

Abstract: The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.

Abstract: Provided is a novel imidazopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.

Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.